Sara M. Tolaney, MD, MPH

Sara M Tolaney, MD is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.

Articles

Experience with Trastuzumab Deruxtecan in Breast Cancer

October 21st 2021

Breast cancer experts, Sara Tolaney, MD, and Mark Pegram, MD, discuss current standard of care in sequencing of therapies in mBC and the effect of DESTINY-Breast03 data on sequencing going forward.

DESTINY-Breast03 Trial in HER2+ mBC

October 21st 2021

Mark Pegram, MD, and Sara Tolaney, MD, review the DESTINY-Breast03 study design, clinical efficacy, and safety data.

Trastuzumab Derxutecan in HER2+ mBC

October 21st 2021

Sara Tolaney, MD, describes trastuzumab deruxtecan and the data that led to its accelerated approval in HER2+ breast cancer.

Historical Perspective of HER2+ Breast Cancer

October 21st 2021

Mark Pegram, MD, provides a historical perspective on recent advancements made in the treatment landscape for patients with HER2-positive breast cancer.

Dr. Tolaney on Key Findings From the ExteNET Trial in HER2+ Breast Cancer

July 29th 2021

Sara M. Tolaney, MD, MPH, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast cancer.

Dr. Tolaney on Tailoring HER2-Directed Therapy in Breast Cancer

July 19th 2021

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer.

Dr. Tolaney on the Need to Develop Additional Biomarkers in mTNBC

January 14th 2021

Sara M. Tolaney, MD, MPH, discusses the need to develop additional biomarkers of response in metastatic triple-negative breast cancer.

Dr. Tolaney on the Safety Profile of SAR439859 in ER+/HER2- Metastatic Breast Cancer

December 10th 2020

Sara M. Tolaney, MD, MPH, discusses the safety profile of SAR439859 in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Tolaney on Escalating Versus De-Escalating Therapies in HER2+ Breast Cancer

October 23rd 2020

Sara M. Tolaney, MD, MPH, discusses escalating versus de-escalating therapies in HER2-positive breast cancer.

Dr. Tolaney on Data With Trastuzumab Deruxtecan in HER2+ Breast Cancer Brain Metastases

October 22nd 2020

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast Cancer

October 3rd 2020

Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.

Dr. Tolaney on the Evolution of Treatment in HER2+ Breast Cancer

October 1st 2020

Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer

July 17th 2020

Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

June 10th 2020

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

June 9th 2020

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Dr. Tolaney on Sequencing Strategies in Metastatic HER2+ Breast Cancer

May 6th 2020

Sara M. Tolaney, MD, MPH, discusses sequencing strategies in metastatic HER2-positive breast cancer.

Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

May 5th 2020

Sara M. Tolaney, MD, MPH, discusses remaining questions with CDK4/6 inhibitors in hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr. Tolaney on Sequencing Questions in Breast Cancer

April 7th 2020

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

March 11th 2020

Sara M. Tolaney, MD, MPH, associate director, Susan F. Smith’s Center for Women’s Cancers, director, Clinical Trials, Breast Oncology, senior physician, Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses considerations for adjuvant therapy in patients with early-stage HER2-positive breast cancer.

Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast Cancer

March 4th 2020

Sara M. Tolaney, MD, MPH, discusses novel approaches in treating patients with HER2-positive breast cancer.